Tempus AI Q4 revenue $200.7M (+35.8% YoY); guides FY25 revenue ~$1.24B, Adj. EBITDA ~$5M

Tempus AI, Inc.

2024-FY EPS reported -$6.23 revenue$693,398,000

Q4 revenue $200.7M (+35.8% YoY); Genomics $120.4M, Data $80.2M. Gross profit $122.1M (+49.7%).
FY24 revenue $693.4M (+30.4%); net loss $705.8M (incl. $547.7M stock comp); Adj. EBITDA loss $104.7M.
Closed Ambry Genetics acquisition Feb 3, 2025; combined FY25 revenue guidance ~$1.24B (+79% YoY).
Expects FY25 Adj. EBITDA ~$5M (improvement of ~$110M over FY24).
CMS reimbursement for Tempus ECG-AF algorithm at $138/test; xT CDx granted ADLT status with $4,500 reimbursement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.